Albutrepenonacog Alfa Drug Aliquot | Coagulation Factor IX | Therapeutic Fusion Protein

Aliquoted from the original reference drug | Now available for research use

Aliquots of the reference drug Albutrepenonacog Alfa are now available as research consumables.

Albutrepenonacog Alfa drug aliquots can be used for in vitro or in vivo experiments. Several other reference drugs are also available.

The drug aliquots are generated by aliquoting (dividing and repackaging) the EU-licensed reference drug.

Not looking for Albutrepenonacog Alfa Reference drug?

Search our therapeutic molecules product database

Quick Ordering

Find and order your therapeutic molecules through smart filters

Multiple Batches

Up to 10 batches of original drugs for examining batch-to-batch variations

Reduce Costs

Up to 80% less compared to the original pharmaceutical price

Worldwide Shipping

Shipment within days worldwide according to GDP-standards

Precise Quantity​​

Up to 80% less compared to the original pharmaceutical price

Idelvion® / Albutrepenonacog Alfa Reference Product

Drug nameIdelvion®
INNAlbutrepenonacog Alfa
API typeAlbutrepenonacog Alfa is a purified protein produced by recombinant DNA technology, generated by the genetic fusion of recombinant albumin to recombinant coagulation factor IX.
Pharmacotherapeutic group
Antihaemorrhagics, blood coagulation factor IX
ATC code
B02BD04
Target of antibody
General functionThe genetic fusion of the cDNA of human albumin to the cDNA of human coagulation factor IX enables the protein to be produced as a single recombinant protein and assures product homogeneity by avoiding chemical conjugation. The recombinant factor IX portion is identical to the Thr148 allelic form of plasma-derived factor IX. The cleavable linker between the recombinant factor IX and albumin molecules is derived from the endogenous “activation peptide” in native factor IX.
Short description
Pharmacodynamic properties
(Mechanism of action; Source EMA document)
Factor IX is a single chain glycoprotein with a molecular mass of about 68,000 Dalton. It is a vitaminK dependent coagulation factor and it is synthesised in the liver. Factor IX is activated by factor XIa in
the intrinsic coagulation pathway and by the factor VII/tissue factor complex in the extrinsic pathway.
Activated factor IX, in combination with activated factor VIII, activates factor X. Activated factor X
converts prothrombin into thrombin. Thrombin then converts fibrinogen into fibrin and a clot is
formed.
Pharmacodynamic properties (Pharmacodynamic effects; Source EMA document)The PK parameters following a single injection of 50 IU/kg of Albutrepenonacog Alfa were based on plasma factor IX activity measured by the one-stage clotting assay. The mean factor IX activity at day 7 and day 14 was 13.76% and 6.10%, respectively, after a single dose of 50 IU/kg IDELVION. Repeat PK assessment for up to 30 weeks demonstrated a stable pharmacokinetic profile and incremental recovery was consistent over time. Trough levels of 5-10% have been targeted in clinical studies for achieving bleeding control while on prophylaxis. PK simulations suggest the time to reach 5% plasma FIX activity following a single injection of 50 IU/kg IDELVION to be 12.5 days for adults.
Original license holder
Marketing authorisation numbers
EU/1/16/1095/002
Marketing authorisation holder
CSL Behring GmbH
Emil-von-Behring-Str. 76
35041 Marburg
Germany
Name of the manufacturer of the biological active substance
CSL Behring GmbH
Emil-von-Behring Strasse 76
35041 Marburg
Germany
Name and address of the manufacturer(s) responsible for batch releaseCSL Behring GmbH
Emil-von-Behring Strasse 76
35041 Marburg
Germany
Max shelf life
3 years
Storage conditions
2°C – 8°C
List of excipients
Powder
Sodium citrate
Polysorbate 80
Mannitol
Sucrose
Hydrochloric acid (for pH adjustment)

Solvent
Water for injections

Evidentic – fast, accurate, secure

Our products are empowering researchers worldwide​

Evidentic offers multiple batches of original drug aliquots in low binding Eppendorf tubes for research use only. We provide licence-free drug aliquots with long, short or even “negative shelf life” by storing the products at recommended temperatures (either 2-8°C or -80°C) and ensuring fully functional molecules for research purposes.

we are recruiting